Cell line · CVCL_1514
Papers48
1 to 20 of 48
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| NAPRT loss promotes lung tumor initiation and growth through AKT signaling independently of NAD+ biosynthesis. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The lncRNA, CyKILRb acts as a ceRNA for tumor suppressive microRNA to augment oncogenic phenotype via induction of PIK3R2/PI3K/AKT axis. | Mol Ther Nucleic Acids | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of SKP2-Recruiting PROTACs for Target Protein Degradation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NRF2 regulates lipid droplet dynamics to prevent lipotoxicity. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PLK1-mediated PDHA1 phosphorylation drives mitochondrial dysfunction, mitophagy, and cancer progression in Cr(VI)-associated lung cancer. | J Biol Chem | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. | Mol Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional-proteomics-based investigation of the cellular response to farnesyltransferase inhibition in lung cancer. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SMURF2 Facilitates GAP17 Isoform 1 Membrane Displacement to Promote Mutant p53-KRAS Oncogenic Synergy. | Mol Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Single-cell and spatial transcriptomics reveal a potential role of ATF3 in brain metastasis of lung adenocarcinoma. | Transl Lung Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 37994369 | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Endogenous spacing enables co-processing of microRNAs and efficient combinatorial RNAi. | Cell Rep Methods | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors. | Mol Cancer Ther | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. | Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. | Elife | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. | Cell Chem Biol | 2020 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1514/papers